Pande Atul 4

What Happened

• Atul Pande, a director of Immunovant, exercised options and sold shares on June 26, 2026. The filing shows he acquired 1,500 shares by exercising at $8.43 per share (cost $12,645) and sold 1,500 shares in an open-market transaction at $38.01 per share (proceeds $57,015). The Form 4 also lists a derivative disposition (code M) at $0.00 related to the exercise/conversion.

Key Details

• Transaction date: 2026-06-26
• Exercise (M): 1,500 shares acquired at $8.43 each — total cost $12,645
• Sale (S): 1,500 shares sold at $38.01 each — gross proceeds $57,015
• Derivative entry: 1,500 shares disposed at $0.00 (related to conversion/exercise)
• Shares owned after transaction: not specified in the provided filing excerpt
• Footnotes: F1 — transaction occurred under a Rule 10b5-1 trading plan adopted Dec 26, 2025; F2 — reflects an award of fully vested stock options
• Timeliness: Filing date matches transaction date (timely)

Context

• The filing shows an exercise of options followed by a sale the same day, which is commonly a cashless exercise or sell-to-cover pattern (exercise to obtain shares, then sell some/ all). The M code on Form 4 denotes exercise/conversion of a derivative (stock option); S denotes an open-market sale.
• The presence of a 10b5-1 plan means the sale was executed under a prearranged trading plan adopted on Dec 26, 2025. This is a common way for insiders to schedule trades and does not, by itself, indicate the insider’s current view of the company.